SOURCE: Patheon


October 21, 2014 09:00 ET

Patheon® to Present Multiple Scientific Findings at 2014 AAPS Annual Meeting and Exposition

DURHAM, NC--(Marketwired - October 21, 2014) - Patheon, the pharmaceutical services business owned by DPx Holdings B.V., will showcase key capabilities and expertise with more than 20 scientists presenting posters on behalf of Patheon and Banner Life Sciences at this year's AAPS Annual Meeting and Exposition from Sunday, Nov. 2 to Thursday, Nov. 6, in San Diego, Calif. The AAPS Annual Meeting and Exposition hosts top scientists from CROs and CMOs in the world each year to update industry leaders on advances in the field of pharmaceutical science.

While at the conference, Patheon will feature OneSource™, the end-to-end early development offering which provides a single, seamless solution to customers for Phase I through Phase II projects, delivering a simplified process for both drug substance to drug products, focusing on simplicity, speed and uncompromised quality.

In addition to the more than 20 Patheon and Banner Life Sciences experts presenting scientific posters, Anil Kane, Ph.D., MBA, Executive Director, Global Formulation Sciences, PDS at Patheon, and Bill Weiser, Ph.D., Global Head, PDS Analytical Sciences at Patheon, will give a corporate presentation focusing on "Solving Challenges from Discovery to Commercial Manufacturing of Drug Substance and Drug Products" on Tuesday, Nov. 4, 1:00-1:15 p.m., in the Corporate Presentation Theatre, located at the end of row 1900.

"I am excited to attend AAPS again this year with our team presenting an impressive number of scientific posters that showcase our capabilities, including solving developmental challenges in manufacturing of tablets, capsules and softgels of immediate, controlled release dosage forms, as well as sterile formulations," said Anil Kane. "AAPS is a leading conference in the industry, and in addition to the capabilities we will be presenting through our posters, we look forward to highlighting and introducing customers to our new OneSource offering."

Executives, technical and scientific experts from Patheon and Banner Life Sciences will be attending AAPS and will be available to discuss the company's full services and capabilities. Representatives can be found at booth #1014 for the duration of the conference. To schedule a meeting in advance, please visit and for press inquiries, please email

About DPx Holdings B.V.
DPx Holdings B.V. is the privately held parent company of the Patheon, DPx Fine Chemicals and Banner Life Sciences businesses. The company is a leading provider of CDMO services, pharmaceutical products and products for other industries. DPx Holdings B.V. was founded in 2014 as a result of the merger of Patheon and DSM Pharmaceutical Products and is owned 51% by JLL Partners and 49% by Royal DSM. With a global headquarters in Durham, N.C., DPx Holdings B.V. has a footprint of more than 20 locations across North America, Europe, Latin America and Australia with more than 8,000 employees. DPx Holdings B.V. offers customers unsurpassed quality, end-to-end services and value through its three business units. For more information, visit

About Patheon®
Patheon® is a leading provider of contract development and commercial manufacturing (CDMO) services to the global pharmaceutical industry for a full array of solid and sterile dosage forms, including small molecule API and biologic drug substances. Patheon, a business unit of DPx Holdings B.V., encompasses the combined commercial manufacturing capabilities and pharmaceutical product development services, as well as offers a full array of biologic services and pharmaceutical active pharmaceutical ingredients (API) development. Patheon is #1 in product development services, #2 in commercial scale product manufacturing and is #1 in quality. For more information, visit

About Banner Life Sciences™
Established in 2013, Banner Life Sciences™ was formed as a result of the acquisition of Banner Pharmacaps by Patheon®. Banner Life Sciences is now a business unit of DPx Holdings B.V. and is dedicated to the research and development, in-licensing, out-licensing and commercialization of innovative formulation technologies, as well as the marketing of prescription, over-the-counter and nutritional proprietary products. For more information, visit

Contact Information